title: [Effects of glycine on auditory evoked potentials among diabetic patients with auditory pathway neuropathy].
abstract: BACKGROUND
  Glycine inhibits the formation of advanced glycation end products that may cause central and peripheral neuronal damage, affecting also the auditory nerve.
  
  
  OBJECTIVE
  To evaluate the effect of glycine on auditory nerve conduction and hearing level among patients with type 2 diabetes mellitus and auditory neuropathy.
  
  
  METHODS
  Twenty grams of oral glycine per day were administered during 6 months to 28 type 2 diabetic patients aged 58 ± 6 years, with auditory pathway neuropathy. Hearing tests and evoked otoacustic potentials were performed regularly. Fifteen diabetic patients aged 49 ± 8 years, without auditory nerve neuropathy did not receive glycine and were followed as a control group.
  
  
  RESULTS
  Among patients receiving glycine, a significant improvement in left ear audiometry at 125, 250 and 500 Hz and right ear audiometry at 500 Hz, was observed. Waves I, III and V (p= 0.02) of evoked otoacustic potentials improved significantly in the left ear and wave I in the right ear. Among controls, waves V and III of evoked otoacoustic potentials had a significant impairment in the left ear.
  
  
  CONCLUSIONS
  There was an improvement in auditory evoked potentials in patients receiving glycine and an impairment in untreated control patients.
authors.affiliation: Hospital General Regional 72, Tlalnepantla, México. malourdes_255@yahoo.com.mx
authors.forename: María de Lourdes
authors.initials: Mde L
authors.lastname: Muñoz-Carlin
authors.forename: José Raymundo
authors.initials: JR
authors.lastname: Rodríguez-Moctezuma
authors.forename: Juan Gerardo
authors.initials: JG
authors.lastname: Gómez Latorre
authors.forename: María Luisa
authors.initials: ML
authors.lastname: Montes-Castillo
authors.forename: Salvador
authors.initials: S
authors.lastname: Juárez-Adauta
mesh_terms: D001299:Audiometry; D001306:Auditory Pathways / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003929:Diabetic Neuropathies / Q000503:physiopathology / Q000628:therapy*; D005072:Evoked Potentials, Auditory / Q000187:drug effects*; D005260:Female; D005998:Glycine / Q000627:therapeutic use*; D018684:Glycine Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D018684:Glycine Agents; D005998:Glycine